Business · India Bureau
Novonesis to invest ₹6,660 crore in Maharashtra biosolutions plant
The Danish biotech firm plans to establish a facility in Maharashtra that will manufacture industrial enzymes for multiple sectors. The plant is expected to reach full operational capacity by 2030.
LSN India ·
Novonesis, a leading bioscience company, has announced plans for a major investment in Maharashtra to establish a cutting-edge biosolutions manufacturing facility. The project will require an investment of ₹6,660 crore and is slated to become fully operational by 2030, positioning the state as a key hub for biochemical production in India.
The facility will specialise in the production of industrial enzymes, catering to diverse end-use sectors across the Indian economy. These include the biofuels industry, household care and personal care products, and food and beverage manufacturing. The diversified product portfolio underscores the facility's strategic importance in supporting multiple high-growth industrial segments.
The investment represents significant confidence in Maharashtra's infrastructure, skilled workforce, and business environment for biotechnology ventures. Such facilities are critical for India's push towards sustainable industrial practices and reducing dependence on imported biochemical inputs. The project aligns with India's broader vision of strengthening domestic bioeconomy capabilities.
Once operational, the facility is expected to contribute to employment generation and technology transfer in the state, while enhancing India's position in global biochemical markets. The timeline through 2030 allows for phased development and capacity scaling to meet projected market demand.